Skip to main content
SpringerLink
Log in

Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Functional interactions between dopamine receptor subtypes may affect behavioral and biochemical responses which serve as models for neuropsychiatric illnesses and the clinical effects of drug therapy. We evaluated the effects of chronic exposure to the selective D1 receptor antagonist SCH 23390, and the selective D2 receptor antagonist metoclopramide, on spontaneous and drug-induced behavior and receptor density in rats, and then determined how these effects would be modified by concurrent administration of antagonists or agonists [SKF 38393, LY 171555 (quinpirole)] selective for the complementary receptor subtype. Administered alone, both the D1 and D2 antagonists had acute cataleptic effects to which animals became tolerant following chronic treatment, but the selective antagonists had opposing effects on spontaneous locomotor activity. Both antagonists produced equivalent, supersensitive behavioral responses to apomorphine, and resulted in an increase in D2 receptor density. Coadministration of the D1 and D2 antagonists had a synergistic effect on catalepsy, attenuated the effects on spontaneous locomotor activity observed with either drug alone, and had an additive effect on both apomorphine-induced stereotypic behavior and D2 receptor proliferation. On the other hand, when either selective antagonist was combined with the agonist selective for the complementary receptor subtype, both D2 receptor proliferation and behavioral supersensitivity were completely blocked. Combined antagonist-agonist treatments had opposing effects on the development of tolerance to antagonist-induced catalepsy. D2 —but not D1 — receptor densities were correlated with animals' behavioral responses to apomorphine. There results support and extend the notion that complex functional interactions between D1 and D2 receptor families occur within the central nervous system, and suggest that novel effects might be derived from combined administration of receptor selective agonists and antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ant J, Perregaard J (1987) Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection. Eur J Pharmacol 143: 45–53

    PubMed  Google Scholar 

  • Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133: 137–145

    PubMed  Google Scholar 

  • Bedard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T (1993) Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In: Narabayaski H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology, vol 60. Raven Press, New York, pp 113–118

    Google Scholar 

  • Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of [3H]SCH23390, a selective D1 receptor antagonist ligand, in rat striatum. Life Sci 35: 1885–1893

    PubMed  Google Scholar 

  • Boyson SJ, McGonigle P, Molinoff PB (1986) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci 6: 3177–3188

    PubMed  Google Scholar 

  • Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131: 301–306

    PubMed  Google Scholar 

  • Braun AR, Chase TN (1988) Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists [published erratum appears in Eur J Pharmacol 154(3): 351–2]. Eur J Pharmacol 147: 441–451

    PubMed  Google Scholar 

  • Campbell A, Baldessarini RJ, Neumeyer JL (1993) Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111: 351–358

    PubMed  Google Scholar 

  • Cheetham SC, Kettle CJ, Martin KF, Heal DJ (1995) D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neural Transm [Gen Sect] 102: 35–46

    Google Scholar 

  • Chipkin RE, McQuade RD, Iorio LC (1987) D1 and D2 binding site upregulation and apomorphine-induced stereotypy. Pharmacol Biochem Behav 28: 477–482

    PubMed  Google Scholar 

  • Costall B, Naylor RJ (1975) The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol 32: 87–92

    PubMed  Google Scholar 

  • Duffy RA, Kaminska G, Chipkin RE, McQuade RD (1992) Selective upregulation of D-1 dopamine receptors following chronic administration of SCH 39166 in primates. Pharmacol Biochem Behav 41: 235–238

    PubMed  Google Scholar 

  • Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS (1990) Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J Neural Transm [PD Sect] 2: 91–100

    Google Scholar 

  • Esposito E, Bunney BS (1989) The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons. Eur J Pharmacol 169: 61–66

    PubMed  Google Scholar 

  • Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. J Neural Transm [Suppl] 36: 43–59

    Google Scholar 

  • Gerfen CR, Engber TM (1992) Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach. Neurol Clin 10: 435–449

    PubMed  Google Scholar 

  • Giorgi O, Pibiri MG, Loi R, Corda MG (1993) Chronic treatment with SCH 23390 increases the production rate of dopamine D1 receptors in the nigrostriatal system of the rat. Eur J Pharmacol 245: 139–145

    PubMed  Google Scholar 

  • Gomez-Mancilla B, Bedard PJ (1991) Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259: 409–413

    PubMed  Google Scholar 

  • Grebb JA, Girault JA, Ehrlich M, Greengard P (1990) Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. J Neurochem 55: 204–207

    PubMed  Google Scholar 

  • Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M (1986) Dopamine receptor changes in response to prolonged treatment with L-dopa. J Neural Transm 22: 33–40

    Google Scholar 

  • Hallett M (1993) Physiology of basal ganglia disorders: an overview. Can J Neurol Sci 20: 177–183

    PubMed  Google Scholar 

  • Hess EJ, Albers LJ, Le H, Creese I (1986) Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238: 846–854

    PubMed  Google Scholar 

  • Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologie effects on D1 and D2 dopamine receptors. J Neurosci 8: 2361–2370

    PubMed  Google Scholar 

  • Hornykiewicz O (1975) Parkinsonism induced by dopaminergic antagonists. Adv Neurol 9: 155–164

    PubMed  Google Scholar 

  • Janssen PA, Awouters FH (1994) Is it possible to predict the clinical effects of neuroleptics from animal data? Part V. From haloperidol and pipamperone to risperidone. Arzneimittelforschung 44: 269–277

    PubMed  Google Scholar 

  • Janssen PA, Niemegeers CJ, Schellekens KH (1966) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Arzneimittelforschung 16: 339–246

    PubMed  Google Scholar 

  • Jenner P, Kerwin R, Rupniak NM, Murugaiah K, Hall MD, Fleminger S, Marsden CD (1983) Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. J Neural Transm [Suppl] 18: 205–212

    Google Scholar 

  • Jenner P, Rupniak NM, Marsden CD (1985) Differential alteration of striatal D-1 and D-2 receptors induced by the long term administration of haloperidol, sulpride or clozapine to rats. Psychopharmacology [Suppl] 2: 174–181

    Google Scholar 

  • Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94: 507–522

    PubMed  Google Scholar 

  • Klawans HL, Goetz CG, Carvey PM (1983) Animals models of tardive dyskinesia. Clin Neuropharmacol 6: 129–135

    PubMed  Google Scholar 

  • LaHoste GJ, Marshall JF (1989) Non-additivity of D2 receptor proliferation induced by dopamine denervation and chronic selective antagonist administration: evidence from quantitative autoradiography indicates a single mechanism of action. Brain Res 502: 223–232

    PubMed  Google Scholar 

  • LaHoste GJ, Marshall JF (1991) Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 41: 473–481

    PubMed  Google Scholar 

  • LaHoste GJ, Marshall JF (1992) Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse 12: 14–26

    PubMed  Google Scholar 

  • Lappalainen J, Hietala J, Koulu M, Seppala T, Sjoholm B, Syvalahti E (1990) Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J Pharmacol Exp Ther 252: 845–852

    PubMed  Google Scholar 

  • Lappalainen J, Hietala J, Pohjalainen T, Syvalahti E (1992) Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210: 195–200

    PubMed  Google Scholar 

  • Laruelle M, Jaskiw GE, Lipska BK, Kolachana B, Casanova MF, Kleinman JE, Weinberger DR (1992) D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res 575: 47–56

    PubMed  Google Scholar 

  • Leysen JE, Gommeren W, Laduron PM (1978) Spiperone, a ligand of choice for neuroleptic receptors. Kinetics and characterization of in vitro binding. Biochem Pharmacol 27: 307–316

    PubMed  Google Scholar 

  • Lowry OH, Rosebrough NJ, Farr AJ, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 163: 265–275

    Google Scholar 

  • Lublin H, Gerlach J, Peacock L (1993) Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity. Psychopharmacology (Berl) 112: 389–397

    Google Scholar 

  • Marin C, Chase TN (1993) Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur J Pharmacol 231: 191–196

    PubMed  Google Scholar 

  • Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN (1993) D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45: 195–200

    PubMed  Google Scholar 

  • Martin-Iverson MT (1991) Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines. Naunyn Schmiedebergs Arch Pharmacol 344: 281–285

    PubMed  Google Scholar 

  • Mashurano M, Waddington JL (1986) Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393. Neuropharmacology 25: 947–949

    PubMed  Google Scholar 

  • McGeer PL, McGeer EG, Schurer U, Singh KA (1977) A glutaminergic corticostriatal path. Brain Res 128: 369–373

    PubMed  Google Scholar 

  • McGonigle P, Boyson SJ, Reuter S, Molinoff PB (1989) Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse 3: 74–82

    PubMed  Google Scholar 

  • Memo M, Pizzi M, Nisoli E, Missale C, Carruba MO, Spano P (1987) Repeated administration of (−)sulpride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in corticallimbic brain regions. Eur J Pharmacol 138: 45–51

    PubMed  Google Scholar 

  • Meyer ME, Cottrell GA, Van Hartesveldt C (1992) Dopamine D1 antagonists potentiate the durations of bar and cling catalepsy and the dorsal immobility response in rats. Pharmacol Biochem Behav 41: 507–510

    PubMed  Google Scholar 

  • Molloy AG, Waddington JL (1988) Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats. Br J Pharmacol 95: 335–342

    PubMed  Google Scholar 

  • Murugaiah K, Fleminger S, Hall MD, Theodorou A, Jenner P, Marsden CD (1984) Alterations in different populations of striatal dopamnine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats. Neuropharmacology 23: 599–609

    PubMed  Google Scholar 

  • Parashos SA, Barone P, Tucci I, Chase TN (1987) Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade. Life Sci 41: 2279–2284

    PubMed  Google Scholar 

  • Parashos SA, Barone P, Marin CA, Paraschos AJ, Kapitzoglou-Logothetis V, Chase TN (1989) Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat. Psychopharmacology (Berl) 98: 189–192

    Google Scholar 

  • Parashos SA, Marin C, Chase TN (1989) Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy. Neurosci Lett 105: 169–173

    PubMed  Google Scholar 

  • Parashos SA, Marin C, Barone P, Kapitzoglou-Logothetis V, Chase TN (1990) Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl) 102: 411–413

    Google Scholar 

  • Parenti M, Flauto C, Parati E, Vescovi A, Groppetti A (1986) Differential effect of repeated treatment with L-dopa on dopamine D-1 of D-2 receptors. Neuropharmacology 25: 331–337

    PubMed  Google Scholar 

  • Paul ML, Graybiel AM, David JC, Robertson HA (1992) D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 12: 3729–3742

    PubMed  Google Scholar 

  • Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, Orlando

    Google Scholar 

  • Robbins TW, Koob GF (1985) Selective disruption of displacement behavior by lesions of the mesolimbic dopamine system. Nature 285: 409

    Google Scholar 

  • Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102: 748–759

    PubMed  Google Scholar 

  • Schettini G, Ventra C, Florio T, Grimaldi M, Meucci O, Marino A (1992) Modulation by GTP of basal and agonist-stimulated striatal adenylate cyclase activity following chronic blockade of D1 and D2 dopamine receptors: involvement of G proteins in the development of receptor supersensitivity. J Neurochem 59: 1667–1674

    PubMed  Google Scholar 

  • See RE, Aravagiri M, Ellison GD (1989) Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors. Life Sci 44: 229–236

    PubMed  Google Scholar 

  • Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4: 2737–2744

    PubMed  Google Scholar 

  • Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1: 5–15

    PubMed  Google Scholar 

  • Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C (1989) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86: 10156–10160

    PubMed  Google Scholar 

  • Smialowski A (1989) Chronic administration of SCH 23390 enhances spontaneous searching and locomotor activity of rats. An open field study. Behav Brain Res 35: 41–44

    PubMed  Google Scholar 

  • Stefanini E, Frau M, Gessa GL (1991) Increase in D2 dopamine receptors in the substantia nigra after chronic (−)-sulpiride treatment. Brain Res 555: 340–342

    PubMed  Google Scholar 

  • Stoof JC, Kebabian JW (1981) Opposing roles for D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366–368

    PubMed  Google Scholar 

  • Vaccheri A, DallÓlio R, Gandolfi O, Roncada P, Montanaro N (1987) Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390. Psychopharmacology 91: 394–396

    PubMed  Google Scholar 

  • Verma A, Kulkarni SK (1992) D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109: 477–483

    PubMed  Google Scholar 

  • Waddington JL, Gamble SJ (1980) Neuroleptic treatment for a substantial proportion of adult life: behavioral sequallae of 9 months haloperidol administration. Eur J Pharmacol 67: 363–369

    PubMed  Google Scholar 

  • Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR (1987) D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236: 719–722

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. A. R. Braun

    Present address: Language Section, Voice Speech and Language Branch, NIDCD, National Institutes of Health, Bethesda, Maryland

Authors and Affiliations

  1. Experimental Therapeutics Branch, NINDS, National Institutes of Health, Bethesda, Maryland

    M. M. Mouradian

  2. Department of Psychiatry, Yale University and West Haven VA Medical Center, West Haven, Connecticut, USA

    M. Laruelle

Authors
  1. A. R. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Laruelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Mouradian
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braun, A.R., Laruelle, M. & Mouradian, M.M. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J. Neural Transmission 104, 341–362 (1997). https://doi.org/10.1007/BF01277656

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01277656

Keywords

Search

Navigation